Skip to content
F2G logo

F2G Alternatives & Competitors

12 companies similar to F2G — The rare fungal disease company

Companies similar to F2G

Solid Biosciences logo — alternative to F2G

Solid Biosciences

#TogetherWeAreSolid

Spero Therapeutics logo — alternative to F2G

Spero Therapeutics

Clinical-stage biotech company focused on rare diseases and diseases with high unmet need

Quercis Pharma logo — alternative to F2G

Quercis Pharma

For a Healthier World

Emmaus Life Sciences, Inc logo — alternative to F2G

Emmaus Life Sciences, Inc

Improving the lives of people with rare disease.

Rival Readout

Competing with F2G? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout
Neurolixis logo — alternative to F2G

Neurolixis

New treatments for central nervous system disorders

ContraFect Corp logo — alternative to F2G

ContraFect Corp

...focused on discovering & developing differentiated biologic therapies for life-threaten...

AusperBio logo — alternative to F2G

AusperBio

Transforming Patient Lives For a Better Tomorrow

Lumos Pharma logo — alternative to F2G

Lumos Pharma

Transforming Lives with Rare Focus

Vicore Pharma AB logo — alternative to F2G
Eiger BioPharmaceuticals logo — alternative to F2G

Eiger BioPharmaceuticals

Developing innovative therapies to treat and cure rare metabolic diseases

Alkeus Pharmaceuticals, Inc. logo — alternative to F2G

Alkeus Pharmaceuticals, Inc.

Transformation in Sight

Versantis logo — alternative to F2G

Versantis

Multiorgan support for rare pediatric and acute liver diseases

About F2G

F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developing therapies for life-threatening invasive fungal infections. Central to F2G's innovation is the creation of a novel cla...

Services

Development of Antifungal Therapies, Research and Development in Fungal Infections, Early Access to Investigational Therapies

Target Customers

Patients with Rare Fungal Infections, Healthcare Providers, Medical Researchers

Business keywords

Biopharmaceutical, Clinical-stage, Fungal Disease, Orotomides, Antifungal Agents, Invasive Fungal Infections, Dihydroorotate Dehydrogenase, Pyrimidine Biosynthesis, Olorofim, Fungicidal Activity, Rare Mould Infections, Phase 3 Trial, Orphan Drug Status, Breakthrough Therapy Designation, Proprietary Genomics Technology

Business Model

B2B, B2D

Revenue Model

Product Sales, Licensing, Service Fee

Frequently Asked Questions

Companies similar to F2G include Solid Biosciences, Spero Therapeutics, Quercis Pharma, Emmaus Life Sciences, Inc, Neurolixis. They work in Biotechnology and Pharmaceutical and share F2G's focus on biopharmaceutical, clinical-stage and breakthrough therapy designation.
Bounce Watch lists 12 companies that share F2G's industries and are closest to it in business tags, services, target customers, business model and size.
F2G, known as "The rare fungal disease company," is a pioneering clinical-stage biopharmaceutical firm headquartered in the United Kingdom. Founded in 1998, the company is at the forefront of developing therapies for life-threatening invasive fungal infections. Central to F2G's innovation is the creation of a novel cla...

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around F2G: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Compiled from the BounceWatch company index. We last looked at F2G on 11 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout